4Sinaikin PM.Categorical diagnosis and a poetics of obligation:an ethical commentary on psychiatric diagnosis and treatment[J].Ethical Hum Sci Serv,2003,5(2):141-148.
9Murray C JL. The Global Burden of Disease[ M]. Boston, Harvard UniversityPress, U. S. A. 1998.
10Skantze K, Melanice E, Horedou P, et al. Cobmparison of quality of life with standard of living in schiiophrenic outpatients[J]. Br J Psychiatry,1992,161:797.
2Walstab J,Rappold G,Niesler B.5-HT(3)receptors:role in diseaseand target of drugs[J].Pharmacol Ther,2010,128(1):146-169.
3Leopoldo M,Lacivita E,Berardi F,et al.Serotonin 5-HT7 receptoragents:Structure-activity relationships and potential therapeuticapplications in central nervous system disorders[J].PharmacolTher,2011,129(2):120-148.
4Griebel G,Beeske S.Is there still a future for neurokinin 3 receptorantagonists as potential drugs for the treatment of psychiatricdiseases?[J].Pharmacol Ther,2012,133(1):116-123.
5Balaratnasingam S,Janca A.Brain Derived Neurotrophic Factor:a novel neurotrophin involved in psychiatric and neurologicaldisorders[J].Pharmacol Ther,2012,134(1):116-124.
6Guidotti A,Grayson DR.A neurochemical basis for an epigeneticvision of psychiatric disorders(1994-2009)[J].Pharmacol Res,2011,64(4):344-349.
7Biddlestone-Thorpe L,Marchi N,Guo K,et al.Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents[J].Adv Drug Delivery Rev,2012,64(7):605-613.
8Patel T,Zhou J,Piepmeier JM,Saltzman WM.Polymeric nanopar-ticles for drug delivery to the central nervous system[J].Adv DrugDelivery Rev,2012,64(7):701-705.
9Lochhead JJ,Thorne RG.Intranasal delivery of biologics to thecentral nervous system[J].Adv Drug Delivery Rev,2012,64(7):614-628.
